[CSCO oral report] the results of the first line treatment of advanced non squamous non-small cell lung cancer with ibi305

On September 19, 2019, China Suzhou Xinda biopharmaceutical (stock code of Hong Kong Stock Exchange: 01801), a biopharmaceutical company dedicated to the research, development, production and sales of innovative drugs for the treatment of major diseases such as cancer and metabolic diseases It is announced today that in the form of oral report at the 22nd National Congress of clinical oncology and 2019 CSCO academic annual conference, the results of randomized, double-blind, three-stage study (ctr20160848) on the efficacy and safety of first-line treatment of advanced non-small cell lung cancer patients with ibi305 (bevacizumab bioequivalent) and bevacizumab combined with paclitaxel / carboplatin were published (September 19, Beijing time)（ Thursday) 11:25am-11:30am) 450 patients were enrolled in ctr20160848 study, among them, ibi305 group (n = 224) and reference drug bevacizumab group (n = 226) As of March 31, 2019, Fas was centralized, and the updated objective response rate (ORR) assessed by the center image was 47.1% and 46.8%, respectively, and the orr ratio was 1.01 (90% CI: 0.846, 1.181), which fell in the grade specified in the study plan In the validity boundary value (0.75, 1.33) As of May 22, 2019, the results showed that the median PFS of the ibi305 and RBV groups evaluated by researchers was 7.3 months and 7.5 months, respectively, with no statistical difference (P = 0.893) Professor lung, a professor of cancer prevention and treatment center of Zhongshan University, said: "lung cancer is the highest incidence rate in China Bevacizumab is one of the important means for the treatment of non-small-cell lung cancer A randomized, double-blind, three-stage study comparing the efficacy and safety of ibi305 and bevacizumab combined with paclitaxel / carboplatin in the first-line treatment of advanced non-small cell lung cancer is satisfactory It is expected that the drug will be approved for market as soon as possible, bringing more treatment options to patients " Dr Zhou Hui, vice president of the Department of cancer science and strategy of XinDa biopharmaceutical science, said: "lung cancer is the highest incidence rate and mortality rate in China, and it is a serious threat to human life and health At present, Cinda biology has eight registered clinical studies in progress, four of which are lung cancer related studies We hope that through our efforts to help solve China's huge unmet clinical needs, benefit the majority of patients " The incidence rate of advanced non squamous cell lung cancer (NSCLC) is the first malignant tumor in China NSCLC accounts for about 80% to 85% of all lung cancer cases, and about 70% of NSCLC patients are not suitable for surgical resection at the time of diagnosis At the same time, a considerable proportion of early NSCLC patients undergoing surgery will have relapse or distant metastasis, and then die of disease progression About 70% of NSCLC patients in China are non scaly NSCLC There is a huge unmet medical demand for first-line treatment of advanced non scaly non-small cell lung cancer Ibi305 is a biological analogue of bevacizumab injection, also known as recombinant anti VEGF humanized monoclonal antibody injection VEGF is an important factor in the process of angiogenesis, which is overexpressed in the endothelial cells of most human tumors Anti VEGF antibody can selectively bind VEGF with high affinity, block the binding of VEGF to its receptors on the surface of vascular endothelial cells, block the transmission of PI3K Akt / PKB and RAS RAF MEK ERK and other signal pathways, thus inhibiting the growth, proliferation and migration of vascular endothelial cells and angiogenesis, reducing vascular permeability, blocking the blood supply of tumor tissues, and inhibiting the growth, proliferation and migration of tumor cells Proliferation and metastasis, inducing apoptosis of tumor cells, so as to achieve the therapeutic effect of anti-tumor On January 29, 2019, the National Drug Administration (nmpa) accepted the new drug listing application (NDA) of ibi305 and included it in the priority review With regard to Xinda biology, it is the ideal and goal of Xinda biology to develop high-quality biological medicine that people can afford Founded in 2011, Xinda biology is committed to the development, production and sale of innovative drugs for the treatment of major diseases such as cancer On October 31, 2018, Cinda biopharmaceutical was listed on the main board of the stock exchange of Hong Kong Limited, stock code: 01801 Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operation mode A product chain including 21 new drug varieties has been established, covering many disease fields such as tumor and metabolic disease Among them, 4 varieties have been selected into the national "major new drug creation" special project, 16 varieties have entered the clinical research, 4 varieties have entered the clinical phase III research, 3 McAb product listing applications have been accepted by the State Food and drug administration, and all of them have been included in the priority review 1 product (sindelimab Injection, trade name: Dabusu ®, English trademark: tyvyt ®) was approved by the State Drug Administration for marketing The first approved indication was recurrent / refractory classic Hodgkin's lymphoma Xinda biology has set up a team of high-end biomedical development and industrialization talents with international advanced level, including many returned experts, and has reached strategic cooperation with international pharmaceutical companies such as Eli Lilly pharmaceutical, adimab, Incyte and Hanmi of South Korea Xinda bio hopes to work with you to improve the development level of China's biopharmaceutical industry, so as to meet the people's drug access and the people's pursuit of life and health Please visit www.innoventbio.com for details For more information, please contact: Media: Email: pr@innoventbio.com Tel.: + 86512-69566088 Investor: Email: ir@innoventbio.com Tel.: + 86512-69566088 this article is reprinted by yaozhi.com The copyright belongs to the original author The purpose of reprinting is to transmit more information and does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.